TG Therapeutics, Inc
Class Period: Sep 15, 2014 to Oct 12, 2016
Lead Plaintiff Deadline: Mar 7, 2017
Summary of Case:
A securities class action has been filed against TG Therapeutics, Inc. ("TGTX") on behalf of all persons who purchased or otherwise acquired shares of TG Therapeutics between September 15, 2014 and October 12, 2016. This case has been filed in the USDC - NY (Southern).
The complaint alleges that, throughout the Class Period, TGTX misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202. The Phase III trial consisted of two parts, Part I evaluating the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately 200 patients, and Part II evaluating the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients.
During the class period TGTX repeatedly assured investors as to the efficacy and potential FDA approval of the treatment, referring to it as a "best-in-class treatment." Then on October 13, 2016, TGTX announced that it would abandon Part II of the study, thus annulling its filed Special Protocol Assessment with the FDA and cutting enrollment and increasing the likelihood that the FDA would not approve the combination treatment.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.